
NAVERIS: Innovating technology for transformative cancer detection and drug development.
Naveris, founded with a mission to revolutionize cancer detection and treatment, focuses on developing advanced technologies for early cancer identification. The company offers highly sensitive blood tests and liquid biopsies designed to detect viral cancers at their earliest stages. Naveris aims to improve patient outcomes by transforming how cancers are detected, facilitating timely interventions, and enhancing drug development and clinical trials.
Notable figures affiliated with Naveris include experts in oncology and biotechnology, contributing to the company's innovative edge. The startup has garnered attention and investment from key players in the healthcare industry, underscoring its potential impact. Naveris' significant achievements include the development of NavDx®, a groundbreaking test that has set new standards in cancer diagnostics. Through its pioneering efforts, Naveris is making substantial strides in improving early cancer detection and patient care.

Thrive Earlier Detection

Micronoma
micronoma.com

Harbinger Health

Pharus Diagnostics
pharusdx.com

Early Detection
cancer.us

Navya Network
navyanetwork.com

Navrogen
navrogen.com

GRAIL
grail.com

Droplet Biosciences
dropletbiosci.com

Oncodea
oncodea.com

Earli
earli.com

Freenome
freenome.com

Foresight Diagnostics
foresight-dx.com

Mercy BioAnalytics
mercybio.com

Torpedo Diagnostics
Companies similar to Naveris include Thrive Earlier Detection, Micronoma, Harbinger Health and Pharus Diagnostics.
Naveris was founded in 2017.
Naveris' headquarters is located in Waltham, MA, US.
Naveris' most recent funding round was for $33.4M (USD) in September 2022.
As of Sep 19, 2022, Naveris has raised a total of $48.8M (USD).
Naveris has 67 employees as of Feb 5, 2024.